Related Experiment Videos
Systematic management of graft-versus-host disease (GVHD)
1Department of Anesthesiology, Fukushima Medical College, Japan.
Abstract:
Patients with graft-versus-host disease (GVHD) develop multiple organ failure (MOF), so systematic management is needed. First, patients should be kept in a clean room. Antibiotics, anti-fungal drugs and gamma-globulins are essential for the prevention and treatment of infections. If patients are hypoxic for the nasal cannula or the mask, continuous positive airway pressure (CPAP) or artificial ventilation must be used. In the treatment of hepatic dysfunction, lactulose, branched chain amino acid, glucagon-insulin, and Prostaglandin E1 (PGE1) are given. If plasma exchanges are ineffective, a bilirubin absorption therapy may remain partially effective. In the treatment of renal failure, diuretics, PGE1 and dopamine are given. Hemofiltration and hemodialysis will be effective. But the effective treatment for post-transfusion GVHD is unavailable, so systematic management of GVHD is no more than allopathic treatment.
Insights
Managing graft-versus-host disease (GVHD) requires addressing multiple organ failure (MOF) through supportive care, including infection prevention and organ-specific treatments. Effective post-transfusion GVHD treatment remains unavailable, highlighting the limitations of current allopathic approaches.
Area of Science:
- Hematology
- Immunology
- Critical Care Medicine
Background:
- Graft-versus-host disease (GVHD) frequently leads to multiple organ failure (MOF) in patients.
- Systematic management strategies are crucial for patients experiencing GVHD complications.
Purpose of the Study:
- To outline a systematic management approach for GVHD patients experiencing MOF.
- To review current therapeutic interventions for organ-specific dysfunction in GVHD.
Main Methods:
- Infection control through clean room environment, antibiotics, antifungals, and gamma-globulins.
- Respiratory support including continuous positive airway pressure (CPAP) or artificial ventilation for hypoxia.
- Pharmacological and supportive treatments for hepatic dysfunction (lactulose, amino acids, insulin, Prostaglandin E1) and renal failure (diuretics, dopamine).
- Interventions for hepatic dysfunction including plasma exchange and bilirubin absorption therapy.
- Renal replacement therapies such as hemofiltration and hemodialysis.
Main Results:
- Supportive care measures are essential for managing GVHD-induced MOF.
- Specific treatments exist for hepatic and renal dysfunction, including pharmacological agents and dialysis.
- Despite interventions, effective treatment for post-transfusion GVHD is currently unavailable.
Conclusions:
- Systematic management of GVHD-induced MOF relies on supportive and organ-specific allopathic treatments.
- The lack of effective treatments for post-transfusion GVHD underscores a significant gap in current medical practice.